enGene (NASDAQ:ENGN) Earns Outperform Rating from Analysts at Raymond James

Equities research analysts at Raymond James began coverage on shares of enGene (NASDAQ:ENGN - Get Free Report) in a note issued to investors on Wednesday, Marketbeat Ratings reports. The firm set an "outperform" rating and a $23.00 price target on the stock. Raymond James' target price would indicate a potential upside of 162.86% from the stock's previous close.

A number of other equities research analysts have also commented on ENGN. Oppenheimer reissued an "outperform" rating and issued a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley restated an "overweight" rating and issued a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th. JMP Securities assumed coverage on enGene in a research note on Monday, November 18th. They set an "outperform" rating and a $18.00 price target for the company. Finally, Citizens Jmp raised enGene to a "strong-buy" rating in a report on Monday, November 18th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, enGene has a consensus rating of "Buy" and a consensus price target of $30.38.

enGene Stock Up 1.7 %

ENGN stock traded up $0.15 during mid-day trading on Wednesday, reaching $8.75. The company's stock had a trading volume of 38,962 shares, compared to its average volume of 109,276. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The business's 50 day moving average price is $7.82 and its 200 day moving average price is $8.36.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.05. Research analysts expect that enGene will post -1.54 earnings per share for the current fiscal year.

Insider Buying and Selling at enGene

In other enGene news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the firm's stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the acquisition, the chief executive officer now owns 10,000 shares in the company, valued at approximately $57,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion acquired 41,639 shares of the firm's stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $5.97 per share, with a total value of $248,584.83. Following the acquisition, the insider now owns 2,059,459 shares in the company, valued at approximately $12,294,970.23. The trade was a 2.06 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 420,965 shares of company stock valued at $2,651,103. 13.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On enGene

A number of institutional investors have recently modified their holdings of the stock. Wolverine Asset Management LLC acquired a new position in shares of enGene during the 3rd quarter worth approximately $37,000. Point72 Asset Management L.P. grew its stake in shares of enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock worth $4,376,000 after purchasing an additional 619,100 shares in the last quarter. SR One Capital Management LP acquired a new position in shares of enGene during the second quarter worth $4,715,000. Franklin Resources Inc. boosted its stake in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after acquiring an additional 389,918 shares in the last quarter. Finally, Logos Global Management LP boosted its stake in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock valued at $11,316,000 after acquiring an additional 400,000 shares in the last quarter. Hedge funds and other institutional investors own 64.16% of the company's stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.